Vera Therapeutics has disclosed that they have reached an agreement with the U.S. Food and Drug Administration (FDA) to expedite the analysis of the Phase 3 trial, ORIGIN, for potential full approval of Atacicept in adults suffering from IgA nephropathy (IgAN). This collaboration aims to fast-track the review process and seeks to provide more efficient access to the treatment. Atacicept is being investigated as a potential therapy for IgAN, a condition impacting thousands of adults globally. The expedited analysis of the Phase 3 trial signifies an important step towards potentially offering this treatment to those in need sooner.